                         SEQUENCE LISTING

<110>  Yissum Research Development Company of the Hebrew 
       University of Jerusalem Ltd.
 
<120>  PEPTIDES FOR THE TREATMENT OF TYPE 2 DIABETES

<130>  YISSUM/0121 PCT

<150>  US 62/517,924
<151>  2017-06-11

<160>  68    

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X1 = an amino acid residue other than Met and His

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X2 = absent or represents a stretch of two amino acid residues 
       selected from the group consisting of: Arg-X8, wherein X8 is any 
       amino acid residue, Asp-Met and Leu-Gln

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X3 = Phe, Tyr, His, Leu, Ala, Ser or Nva

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X4 = Thr or Gln

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X5 =  Val or Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X6 = absent or selected from a positively charged amino acid 
       residue, Ser and Val

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X7 = absent or represents a positively charged amino acid 
       residue, optionally conjugated with a label

<400>  1

Xaa Xaa Xaa Xaa Lys Gly Gln Xaa Thr Xaa Xaa 
1               5                   10      


<210>  2
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= an amino acid residue other than Met and His

<400>  2

Xaa Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  3
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= an amino acid residue other than Met and His

<400>  3

Xaa Asp Met Phe Thr Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  4
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= an amino acid residue other than Met and His

<400>  4

Xaa Leu Gln Ser Thr Lys Gly Gln Ser Thr Ser 
1               5                   10      


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= an amino acid residue other than Met and His

<400>  5

Xaa Leu Gln Ser Gln Lys Gly Gln Ser Thr Ser 
1               5                   10      


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X=an amino acid residue other than Met and His

<400>  6

Xaa Arg Gly Phe Gln Lys Gly Gln Val Thr Val 
1               5                   10      


<210>  7
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X = an amino acid residue other than Met

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X = absent or represents Arg-Asn

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X = Phe, Tyr, His, Leu, Ala or Nva

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X = Thr or Gln

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X = absent or represents a positively charged amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X = absent or represents a positively charged amino acid residue,
       optionally conjugated with a label

<400>  7

Xaa Xaa Xaa Xaa Lys Gly Gln Val Thr Xaa Xaa 
1               5                   10      


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X= absent or represents Arg-Asn

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X= Phe, Tyr, His, Leu, Ala or Nva

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Thr or Gln

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X= absent or represents a positively charged amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X= absent or represents a positively charged amino acid residue, 
       optionally conjugated with a label

<400>  8

Gly Xaa Xaa Xaa Lys Gly Gln Val Thr Xaa Xaa 
1               5                   10      


<210>  9
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  9

Gly Arg Asn Phe Gln 
1               5   


<210>  10
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  10

Gly Arg Asn His Gln 
1               5   


<210>  11
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  11

Gly Arg Asn Leu Gln 
1               5   


<210>  12
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Norvaline (Nva)

<400>  12

Gly Arg Asn Xaa Gln 
1               5   


<210>  13
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  13

Gly Arg Asn Ala Gln 
1               5   


<210>  14
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  14

Gly Arg Asn Tyr Gln 
1               5   


<210>  15
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  15

Gly Phe Thr 
1           


<210>  16
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= an amino acid residue other than Met

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Phe, Tyr, His, Leu, Ala or Nva

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X= absent or represents a positively charged amino acid residue, 
       optionally conjugated with a label

<400>  16

Xaa Arg Asn Xaa Gln Lys Gly Gln Val Thr Arg Xaa 
1               5                   10          


<210>  17
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Phe, Tyr, His, Leu, Ala or Nva

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  X= absent or represents a positively charged amino acid residue, 
       optionally modified with a label

<400>  17

Gly Arg Asn Xaa Gln Lys Gly Gln Val Thr Arg Xaa 
1               5                   10          


<210>  18
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  18

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  19
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  19

Gly Arg Asn His Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  20
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  20

Gly Arg Asn Leu Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  21
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nva

<400>  21

Gly Arg Asn Xaa Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  22
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Lys modified with a label

<400>  22

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Lys 
1               5                   10          


<210>  23
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  23

Gly Arg Asn Ala Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  24
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  24

Gly Arg Asn Tyr Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  25
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Lys modified with a label

<400>  25

Gly Arg Asn Tyr Gln Lys Gly Gln Val Thr Arg Lys 
1               5                   10          


<210>  26
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= an amino acid residue other than Met

<400>  26

Xaa Phe Thr Lys Gly Gln Val Thr 
1               5               


<210>  27
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  27

Gly Phe Thr Lys Gly Gln Val Thr 
1               5               


<210>  28
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  28

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  29
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal stearoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  29

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  30
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal palmitoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  30

Gly Arg Asn His Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  31
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal stearoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  31

Gly Arg Asn His Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  32
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  32

Gly Arg Asn Leu Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  33
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nva

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  33

Gly Arg Asn Xaa Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  34
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Lys modified with biotin; C-terminal amide group

<400>  34

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Lys 
1               5                   10          


<210>  35
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  35

Gly Arg Asn Ala Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  36
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal palmitoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  36

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  37
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal stearoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  37

Gly Arg Asn Tyr Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  38
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal stearoyl group

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Lys modified with a dansyl group; C-terminal amide group

<400>  38

Gly Arg Asn Tyr Gln Lys Gly Gln Val Thr Arg Lys 
1               5                   10          


<210>  39
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  C-terminal amide group

<400>  39

Gly Phe Thr Lys Gly Gln Val Thr 
1               5               


<210>  40
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= any amino acid residue

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X= absent or represents a stretch of two amino acid residues 
       selected from: Arg-X8, wherein X8 is any amino acid residue, 
       Asp-Met and Leu-Gln

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X= Phe, Tyr, His, Leu, Ala, Ser or Nva

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Thr or Gln

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X= Val or Ser

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X= absent or selected from a positively charged amino acid 
       residue, Ser and Val

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X= absent or represents a positively charged amino acid residue, 
       optionally conjugated with a label

<400>  40

Xaa Xaa Xaa Xaa Lys Gly Gln Xaa Thr Xaa Xaa 
1               5                   10      


<210>  41
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= any amino acid

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Phe, Tyr, His, Leu, Ala or Nva

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  X=Thr or Gln

<400>  41

Xaa Arg Asn Xaa Xaa Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  42
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X= Phe, Tyr, His, Leu, Ala or Nva

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Thr or Gln

<400>  42

Arg Asn Xaa Xaa Lys Gly Gln Val Thr Arg 
1               5                   10  


<210>  43
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= a stretch of 0-10 amino acid residues

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X= an amino acid residue other than Met

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X= Phe, Tyr, His, Leu or Nva

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Thr or Gln

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  X= Lys, D-Lys, AcLys, Arg or Orn

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  X= a stretch of 0-10 amino acid residues

<400>  43

Xaa Xaa Xaa Xaa Xaa Gly Gln Val Xaa 
1               5                   


<210>  44
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nle

<400>  44

Gly Gln Phe Xaa Arg 
1               5   


<210>  45
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoy group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  45

Gly Arg Asn Tyr Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  46
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amide group

<400>  46

Gly Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   


<210>  47
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal RhodaminB

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  47

Gly Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  48
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nle

<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  C-terminal amide group

<400>  48

Gly Gln Phe Xaa Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10                  


<210>  49
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X= Nle

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amide group

<400>  49

Gly Xaa Phe Thr Lys Gly Gln Val Thr 
1               5                   


<210>  50
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amide group

<400>  50

Gly Phe Thr Lys Gly Gln Val Thr Thr 
1               5                   


<210>  51
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Lys modified with biotin; C-terminal amide group

<400>  51

Gly Phe Thr Lys Gly Gln Val Thr Lys 
1               5                   


<210>  52
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal RhodamineB

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  C-terminal amide group

<400>  52

Gly Phe Thr Lys Gly Gln Val Thr 
1               5               


<210>  53
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  53

Gly Arg Asn Phe Thr Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  54
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal stearoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  54

Gly Arg Asn His Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  55
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nle

<400>  55

Gly Gln Phe Xaa 
1               


<210>  56
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  56

Phe Thr Lys Gly Gln Val Thr 
1               5           


<210>  57
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  57

Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10  


<210>  58
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X= a stretch of 0-10 amino acid residues

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  X= Phe, Tyr, His, Leu or Nva

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  X= Thr or Gln

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Lys, D-Lys, AcLys, Arg or Orn

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X= a stretch of 0-10 amino acid residues

<400>  58

Xaa Xaa Xaa Xaa Gly Gln Val Xaa 
1               5               


<210>  59
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nle

<400>  59

Gly Gln Phe Xaa Arg Asn 
1               5       


<210>  60
<211>  19
<212>  PRT
<213>  Homo sapiens

<400>  60

Glu Phe Met Arg Asn Phe Gln Lys Gly Gln Val Thr Arg Asp Gly Phe 
1               5                   10                  15      


Lys Leu Val 
            


<210>  61
<211>  19
<212>  PRT
<213>  Homo sapiens

<400>  61

Thr His His Asp Met Phe Thr Lys Gly Gln Val Thr Thr Gly Gln Tyr 
1               5                   10                  15      


Arg Met Leu 
            


<210>  62
<211>  21
<212>  PRT
<213>  Homo sapiens

<400>  62

Glu Phe Ala Leu Ala Arg Gly Phe Gln Lys Gly Gln Val Thr Val Thr 
1               5                   10                  15      


Gln Pro Tyr Pro Ala 
            20      


<210>  63
<211>  10
<212>  PRT
<213>  Homo sapiens

<400>  63

Arg Asn Phe Gln Lys Gly Gln Val Thr Arg 
1               5                   10  


<210>  64
<211>  10
<212>  PRT
<213>  Homo sapiens

<400>  64

Asp Met Phe Thr Lys Gly Gln Val Thr Thr 
1               5                   10  


<210>  65
<211>  10
<212>  PRT
<213>  Homo sapiens

<400>  65

Arg Gly Phe Gln Lys Gly Gln Val Thr Val 
1               5                   10  


<210>  66
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide

<400>  66

Arg Phe Gln Lys Gly Gln Val Thr 
1               5               


<210>  67
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  67

Gly Arg Asn Ile Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


<210>  68
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X= Nle

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  C-terminal amide group

<400>  68

Gly Arg Asn Xaa Gln Lys Gly Gln Val Thr Arg 
1               5                   10      


